<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2245">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00784225</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000617778</org_study_id>
    <secondary_id>S0000B</secondary_id>
    <secondary_id>U10CA037429</secondary_id>
    <secondary_id>R01EY014418</secondary_id>
    <nct_id>NCT00784225</nct_id>
  </id_info>
  <brief_title>S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000</brief_title>
  <acronym>SEE</acronym>
  <official_title>S0000B: Prevention of Cataract and Age-Related Macular Degeneration With Vitamin E and Selenium - SELECT Eye Endpoints (SEE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Aging may affect a person's vision. Vitamin E and/or selenium may help prevent&#xD;
      cataracts or age-related macular degeneration in men receiving these drugs as part of a&#xD;
      clinical trial for the prevention of prostate cancer.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying vitamin E and/or selenium to see how well they work&#xD;
      in preventing cataract and age-related macular degeneration in men enrolled on SELECT&#xD;
      (SWOG-S0000).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To test whether vitamin E and/or selenium reduces the risk of visually significant&#xD;
           age-related macular degeneration (AMD) in men enrolled on SELECT (SWOG-S0000).&#xD;
&#xD;
        -  To test whether vitamin E and/or selenium reduces the risk of cataract in these&#xD;
           participants.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To test whether vitamin E and/or selenium reduces the risk of advanced AMD in these&#xD;
           participants.&#xD;
&#xD;
        -  To test whether vitamin E and/or selenium reduces the risk of cataract surgery and&#xD;
           subtypes in these participants.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Data from medical records obtained from the participant's ophthalmologist or optometrist are&#xD;
      reviewed. Information from these records is then used to confirm baseline reports of&#xD;
      age-related macular degeneration (AMD) as well as 6-month and annual reports of new diagnoses&#xD;
      of AMD and cataract (or cataract surgery) made since the start of this study. Detailed&#xD;
      questionnaires are also obtained from the participant's ophthalmologist or optometrist to&#xD;
      provide information about the reported AMD or cataract diagnosis (e.g., date of initial&#xD;
      diagnosis; best-corrected visual acuity at the time of diagnosis; date when visual acuity was&#xD;
      first noted to be 20/30 or worse [if different from the date of initial diagnosis];&#xD;
      pathological findings observed when AMD was first diagnosed [e.g., drusen, retinal pigment&#xD;
      epithelial hypo/hyperpigmentation, geographic atrophy, retinal pigment epithelial detachment,&#xD;
      subretinal neovascular membrane, or disciform scar]; pathological findings observed when&#xD;
      visual acuity was first noted to be 20/30 or worse; date when exudative [wet] AMD was first&#xD;
      noted; presence of other ocular abnormalities that could explain or contribute to visual&#xD;
      loss; whether AMD or cataract, by itself, are significant enough to cause vision to be&#xD;
      reduced to 20/30 or worse; whether laser treatment or photodynamic therapy was performed for&#xD;
      AMD; date of cataract extraction; etiology of cataract [e.g., age-related, traumatic,&#xD;
      congenital, inflammatory, or surgery- or steroid-induced]; and cataract type [e.g., nuclear,&#xD;
      cortical, posterior subcapsular, or other]).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Visually Significant Age-related Macular Degeneration (AMD)</measure>
    <time_frame>Every 6 months, up to 7 years</time_frame>
    <description>Visually significant age-related AMD was defined as incident AMD responsible for reduction in best corrected visual acuity to 20/30 or worse(AMD 20/30)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Cataract and Best Corrected Visual-acuity of 20/30</measure>
    <time_frame>Every 6 months, up to 7 years</time_frame>
    <description>Incident cataract was defined as lens opacity diagnosed after randomization but prior to end of study, age-related in origin, and best-corrected visual acuity of 20/30 or worse attributable to the opacity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Advanced AMD</measure>
    <time_frame>Every 6 months, up to 7 years</time_frame>
    <description>Advanced AMD was defined as the occurrence of disciform scars, or geographic atrophy or retinal pigment epithelium (RPE) detachment in either or both eyes at AMD diagnosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Underwent Cataract Extraction</measure>
    <time_frame>Every 6 months, up to 7 years</time_frame>
    <description>Cataract extraction was defined as the surgical removal of an incident cataract.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">13475</enrollment>
  <condition>Cataract</condition>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Vitamin E + selenium placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin E and selenium placebo daily for 7-12 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selenium + vitamin E placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>selenium and vitamin E placebo daily for 7-12 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin E + selenium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin E and selenium placebo daily for 7-12 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin E placebo + selenium placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vitamin E placebo and selenium placebo daily for 7-12 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>selenium</intervention_name>
    <description>200 mcg daily for 7-12 years</description>
    <arm_group_label>Selenium + vitamin E placebo</arm_group_label>
    <arm_group_label>Vitamin E + selenium</arm_group_label>
    <other_name>L-selenomethionine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin E</intervention_name>
    <description>400 IU daily by mouth for 7-12 years</description>
    <arm_group_label>Vitamin E + selenium</arm_group_label>
    <arm_group_label>Vitamin E + selenium placebo</arm_group_label>
    <other_name>alpha tocopherol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin E placebo</intervention_name>
    <description>daily for 7-12 years</description>
    <arm_group_label>Selenium + vitamin E placebo</arm_group_label>
    <arm_group_label>Vitamin E placebo + selenium placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>selenium placebo</intervention_name>
    <description>daily for 7-12 years</description>
    <arm_group_label>Selenium + vitamin E placebo</arm_group_label>
    <arm_group_label>Vitamin E + selenium placebo</arm_group_label>
    <arm_group_label>Vitamin E placebo + selenium placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Enrolled on the Selenium and Vitamin E Prostate Cancer Prevention Trial (SELECT)&#xD;
             SWOG-S0000&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Age-related macular degeneration (AMD) at baseline or at follow-up&#xD;
&#xD;
               -  Cataract or a cataract extraction at follow-up (Closed for accrual as of&#xD;
                  10/01/29)&#xD;
&#xD;
                    -  Participants with a prior diagnosis of cataract at baseline followed by&#xD;
                       another cataract event (cataract diagnosis or a cataract extraction) at&#xD;
                       follow-up are not eligible&#xD;
&#xD;
                    -  Participants with a prior diagnosis of cataract at baseline followed by a&#xD;
                       diagnosis of AMD at follow-up are eligible&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not applicable&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Christen, ScD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber/Brigham and Women's Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harvard Medical School</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 31, 2008</study_first_submitted>
  <study_first_submitted_qc>October 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2008</study_first_posted>
  <results_first_submitted>May 10, 2019</results_first_submitted>
  <results_first_submitted_qc>July 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2019</results_first_posted>
  <last_update_submitted>August 2, 2019</last_update_submitted>
  <last_update_submitted_qc>August 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cataract</keyword>
  <keyword>advanced macular degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 19, 2009</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT00784225/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Selenium + Vitamin E Placebo</title>
          <description>Patients received selenium and vitamin E placebo daily for 7 - 12 years&#xD;
Selenium: 200 mcg daily for 7 - 12 years&#xD;
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years</description>
        </group>
        <group group_id="P2">
          <title>Selenium + Vitamin E</title>
          <description>Patients received selenium and vitamin E daily for 7 - 12 years&#xD;
Selenium: 200 mcg 1 pill by mouth daily for 7 - 12 years&#xD;
Vitamin E: 400 IU daily by mouth for 7 - 12 years</description>
        </group>
        <group group_id="P3">
          <title>Vitamin E Placebo + Selenium Placebo</title>
          <description>Patients received vitamin E placebo and selenium placebo daily for 7 - 12 years&#xD;
Vitamin E placebo:1 pill daily by mouth for 7 - 12 years&#xD;
Selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
        </group>
        <group group_id="P4">
          <title>Vitamin E + Selenium Placebo</title>
          <description>Patients received vitamin E and selenium placebo daily for 7 - 12 years&#xD;
Vitamin E: 400 IU by mouth daily for 7 - 12 years&#xD;
Selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3375"/>
                <participants group_id="P2" count="3357"/>
                <participants group_id="P3" count="3369"/>
                <participants group_id="P4" count="3374"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3375"/>
                <participants group_id="P2" count="3357"/>
                <participants group_id="P3" count="3369"/>
                <participants group_id="P4" count="3374"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants at SELECT sites with IRB approval for SEE and who agreed to participate in SEE or were willing to be contacted about registering to SEE if they were to have an eye event were registered to AMD (13389) and Cataract (11267) portions. There was overlap between the two populations.</population>
      <group_list>
        <group group_id="B1">
          <title>Selenium + Vitamin E Placebo</title>
          <description>Selenium and vitamin E placebo daily for 7-12 years.&#xD;
Selenium: 200 mcg daily for 7 - 12 years&#xD;
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years</description>
        </group>
        <group group_id="B2">
          <title>Selenium + Vitamin E</title>
          <description>Selenium and vitamin E daily for 7-12 years. Selenium: 200 mcg daily for 7 - 12 years&#xD;
Vitamin E: 400 IU daily by mouth for 7 - 12 years</description>
        </group>
        <group group_id="B3">
          <title>Vitamin E Placebo + Selenium Placebo</title>
          <description>Vitamin E placebo and selenium placebo daily for 7-12 years.&#xD;
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years&#xD;
Selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
        </group>
        <group group_id="B4">
          <title>Vitamin E + Selenium Placebo</title>
          <description>Vitamin E and selenium placebo daily for 7-12 years.&#xD;
Vitamin E: 400 IU daily by mouth for 7 - 12 years&#xD;
Selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3375"/>
            <count group_id="B2" value="3357"/>
            <count group_id="B3" value="3369"/>
            <count group_id="B4" value="3374"/>
            <count group_id="B5" value="13475"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="58" upper_limit="68"/>
                    <measurement group_id="B2" value="62" lower_limit="58" upper_limit="67"/>
                    <measurement group_id="B3" value="62" lower_limit="58" upper_limit="67"/>
                    <measurement group_id="B4" value="62" lower_limit="57" upper_limit="67"/>
                    <measurement group_id="B5" value="62" lower_limit="58" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>50-54 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="159"/>
                    <measurement group_id="B4" value="155"/>
                    <measurement group_id="B5" value="608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>55-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1951"/>
                    <measurement group_id="B2" value="1964"/>
                    <measurement group_id="B3" value="1959"/>
                    <measurement group_id="B4" value="2027"/>
                    <measurement group_id="B5" value="7901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1065"/>
                    <measurement group_id="B2" value="1067"/>
                    <measurement group_id="B3" value="1061"/>
                    <measurement group_id="B4" value="993"/>
                    <measurement group_id="B5" value="4186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="190"/>
                    <measurement group_id="B4" value="199"/>
                    <measurement group_id="B5" value="780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3375"/>
                    <measurement group_id="B2" value="3357"/>
                    <measurement group_id="B3" value="3369"/>
                    <measurement group_id="B4" value="3374"/>
                    <measurement group_id="B5" value="13475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2753"/>
                    <measurement group_id="B2" value="2756"/>
                    <measurement group_id="B3" value="2750"/>
                    <measurement group_id="B4" value="2763"/>
                    <measurement group_id="B5" value="11022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="622"/>
                    <measurement group_id="B2" value="601"/>
                    <measurement group_id="B3" value="619"/>
                    <measurement group_id="B4" value="611"/>
                    <measurement group_id="B5" value="2453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education (highest level)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;= High school graduate or GED</title>
                  <measurement_list>
                    <measurement group_id="B1" value="653"/>
                    <measurement group_id="B2" value="641"/>
                    <measurement group_id="B3" value="706"/>
                    <measurement group_id="B4" value="656"/>
                    <measurement group_id="B5" value="2656"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Some college/vocational school</title>
                  <measurement_list>
                    <measurement group_id="B1" value="943"/>
                    <measurement group_id="B2" value="943"/>
                    <measurement group_id="B3" value="948"/>
                    <measurement group_id="B4" value="964"/>
                    <measurement group_id="B5" value="3798"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;College graduate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1759"/>
                    <measurement group_id="B2" value="1752"/>
                    <measurement group_id="B3" value="1705"/>
                    <measurement group_id="B4" value="1738"/>
                    <measurement group_id="B5" value="6954"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown/missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarette smoking</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Never</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1451"/>
                    <measurement group_id="B2" value="1419"/>
                    <measurement group_id="B3" value="1366"/>
                    <measurement group_id="B4" value="1457"/>
                    <measurement group_id="B5" value="5693"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Current</title>
                  <measurement_list>
                    <measurement group_id="B1" value="248"/>
                    <measurement group_id="B2" value="278"/>
                    <measurement group_id="B3" value="319"/>
                    <measurement group_id="B4" value="268"/>
                    <measurement group_id="B5" value="1113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Former</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1670"/>
                    <measurement group_id="B2" value="1654"/>
                    <measurement group_id="B3" value="1681"/>
                    <measurement group_id="B4" value="1642"/>
                    <measurement group_id="B5" value="6647"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Rarely/never</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="59"/>
                    <measurement group_id="B5" value="226"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=1 drink/month</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3325"/>
                    <measurement group_id="B2" value="3304"/>
                    <measurement group_id="B3" value="3303"/>
                    <measurement group_id="B4" value="3314"/>
                    <measurement group_id="B5" value="13246"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (kg/m^2)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;25</title>
                  <measurement_list>
                    <measurement group_id="B1" value="674"/>
                    <measurement group_id="B2" value="666"/>
                    <measurement group_id="B3" value="675"/>
                    <measurement group_id="B4" value="626"/>
                    <measurement group_id="B5" value="2641"/>
                  </measurement_list>
                </category>
                <category>
                  <title>25-&lt;30</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1574"/>
                    <measurement group_id="B2" value="1607"/>
                    <measurement group_id="B3" value="1591"/>
                    <measurement group_id="B4" value="1606"/>
                    <measurement group_id="B5" value="6378"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=30</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1127"/>
                    <measurement group_id="B2" value="1084"/>
                    <measurement group_id="B3" value="1103"/>
                    <measurement group_id="B4" value="1142"/>
                    <measurement group_id="B5" value="4456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1339"/>
                    <measurement group_id="B2" value="1320"/>
                    <measurement group_id="B3" value="1374"/>
                    <measurement group_id="B4" value="1301"/>
                    <measurement group_id="B5" value="5334"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2036"/>
                    <measurement group_id="B2" value="2037"/>
                    <measurement group_id="B3" value="1995"/>
                    <measurement group_id="B4" value="2073"/>
                    <measurement group_id="B5" value="8141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aspirin use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1484"/>
                    <measurement group_id="B2" value="1454"/>
                    <measurement group_id="B3" value="1505"/>
                    <measurement group_id="B4" value="1481"/>
                    <measurement group_id="B5" value="5924"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1891"/>
                    <measurement group_id="B2" value="1903"/>
                    <measurement group_id="B3" value="1864"/>
                    <measurement group_id="B4" value="1893"/>
                    <measurement group_id="B5" value="7551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Statin use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="884"/>
                    <measurement group_id="B2" value="886"/>
                    <measurement group_id="B3" value="900"/>
                    <measurement group_id="B4" value="914"/>
                    <measurement group_id="B5" value="3584"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2464"/>
                    <measurement group_id="B2" value="2447"/>
                    <measurement group_id="B3" value="2451"/>
                    <measurement group_id="B4" value="2434"/>
                    <measurement group_id="B5" value="9796"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="353"/>
                    <measurement group_id="B2" value="348"/>
                    <measurement group_id="B3" value="380"/>
                    <measurement group_id="B4" value="339"/>
                    <measurement group_id="B5" value="1420"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3022"/>
                    <measurement group_id="B2" value="3009"/>
                    <measurement group_id="B3" value="2989"/>
                    <measurement group_id="B4" value="3035"/>
                    <measurement group_id="B5" value="12055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Records sought</title>
          <description>Participants were asked to consent to participate in S0000B, which required them to complete a medical release with information about their ophthalmologic provider. Using this information, Providers were sent a form to complete describing the cataract/cataract extraction/AMD (as applicable) in detail.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="635"/>
                    <measurement group_id="B2" value="624"/>
                    <measurement group_id="B3" value="624"/>
                    <measurement group_id="B4" value="629"/>
                    <measurement group_id="B5" value="2512"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2740"/>
                    <measurement group_id="B2" value="2733"/>
                    <measurement group_id="B3" value="2745"/>
                    <measurement group_id="B4" value="2745"/>
                    <measurement group_id="B5" value="10963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Included in cataract analysis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2805"/>
                    <measurement group_id="B2" value="2789"/>
                    <measurement group_id="B3" value="2829"/>
                    <measurement group_id="B4" value="2844"/>
                    <measurement group_id="B5" value="11267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="570"/>
                    <measurement group_id="B2" value="568"/>
                    <measurement group_id="B3" value="540"/>
                    <measurement group_id="B4" value="530"/>
                    <measurement group_id="B5" value="2208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Included in AMD analysis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3348"/>
                    <measurement group_id="B2" value="3342"/>
                    <measurement group_id="B3" value="3355"/>
                    <measurement group_id="B4" value="3344"/>
                    <measurement group_id="B5" value="13389"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Visually Significant Age-related Macular Degeneration (AMD)</title>
        <description>Visually significant age-related AMD was defined as incident AMD responsible for reduction in best corrected visual acuity to 20/30 or worse(AMD 20/30)</description>
        <time_frame>Every 6 months, up to 7 years</time_frame>
        <population>Marginal analyses were performed with arms pooled based on active vs. placebo selenium or vitamin E.</population>
        <group_list>
          <group group_id="O1">
            <title>AMD: Selenium Active</title>
            <description>Patients received selenium and either Vitamin E or vitamin E placebo daily for 7 - 12 years&#xD;
Selenium: 200 mcg daily for 7 - 12 years&#xD;
Vitamin E: 400 IU daily by mouth for 7 - 12 years&#xD;
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years</description>
          </group>
          <group group_id="O2">
            <title>AMD: Selenium Placebo</title>
            <description>Patients received selenium placebo and either Vitamin E or vitamin E placebo daily for 7 - 12 years&#xD;
Selenium placebo: 1 pill by mouth daily for 7 - 12 years&#xD;
Vitamin E: 400 IU daily by mouth for 7 - 12 years&#xD;
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years</description>
          </group>
          <group group_id="O3">
            <title>AMD: Vitamin E Active</title>
            <description>Patients received vitamin E and either selenium or selenium placebo daily for 7 - 12 years&#xD;
Vitamin E: 400 IU daily by mouth for 7 - 12 years&#xD;
Selenium: 200 mcg daily for 7 - 12 years&#xD;
Selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
          </group>
          <group group_id="O4">
            <title>AMD: Vitamin E Placebo</title>
            <description>Patients received vitamin E placebo and either selenium or selenium placebo daily for 7 - 12 years&#xD;
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years&#xD;
Selenium: 200 mcg daily for 7 - 12 years&#xD;
Selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Visually Significant Age-related Macular Degeneration (AMD)</title>
          <description>Visually significant age-related AMD was defined as incident AMD responsible for reduction in best corrected visual acuity to 20/30 or worse(AMD 20/30)</description>
          <population>Marginal analyses were performed with arms pooled based on active vs. placebo selenium or vitamin E.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6690"/>
                <count group_id="O2" value="6699"/>
                <count group_id="O3" value="6686"/>
                <count group_id="O4" value="6703"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>AMD cases</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>non-AMD cases</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6681"/>
                    <measurement group_id="O2" value="6687"/>
                    <measurement group_id="O3" value="6677"/>
                    <measurement group_id="O4" value="6691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for number of participants with visually significant AMD in SEE sites during pill-taking for selenium</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.52</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for number of participants with visually significant AMD in SEE sites during pill-taking for vitamin E</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Cataract and Best Corrected Visual-acuity of 20/30</title>
        <description>Incident cataract was defined as lens opacity diagnosed after randomization but prior to end of study, age-related in origin, and best-corrected visual acuity of 20/30 or worse attributable to the opacity.</description>
        <time_frame>Every 6 months, up to 7 years</time_frame>
        <population>Marginal analyses were performed with arms pooled based on active vs. placebo selenium or vitamin E.</population>
        <group_list>
          <group group_id="O1">
            <title>Cataract: Selenium Active</title>
            <description>Patients received selenium and either vitamin E or vitamin E placebo daily for 7 - 12 years&#xD;
Selenium: 200 mcg daily for 7 - 12 years&#xD;
Vitamin E: 400 IU daily by mouth for 7 - 12 years&#xD;
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years</description>
          </group>
          <group group_id="O2">
            <title>Cataract: Selenium Placebo</title>
            <description>Patients received selenium placebo and either vitamin E or vitamin E placebo daily for 7 - 12 years&#xD;
Selenium placebo: 1 pill by mouth daily for 7 - 12 years&#xD;
Vitamin E: 400 IU daily by mouth for 7 - 12 years&#xD;
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years</description>
          </group>
          <group group_id="O3">
            <title>Cataract: Vitamin E Active</title>
            <description>Patients received vitamin E and either selenium or selenium placebo daily for 7 - 12 years&#xD;
Vitamin E: 400 IU daily by mouth for 7 - 12 years&#xD;
Selenium: 200 mcg daily for 7 - 12 years&#xD;
Selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
          </group>
          <group group_id="O4">
            <title>Cataract: Vitamin E Placebo</title>
            <description>Patients received vitamin E placebo and either selenium or selenium placebo daily for 7 - 12 years&#xD;
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years&#xD;
Selenium: 200 mcg daily for 7 - 12 years&#xD;
Selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cataract and Best Corrected Visual-acuity of 20/30</title>
          <description>Incident cataract was defined as lens opacity diagnosed after randomization but prior to end of study, age-related in origin, and best-corrected visual acuity of 20/30 or worse attributable to the opacity.</description>
          <population>Marginal analyses were performed with arms pooled based on active vs. placebo selenium or vitamin E.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5594"/>
                <count group_id="O2" value="5673"/>
                <count group_id="O3" value="5633"/>
                <count group_id="O4" value="5634"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Cataract cases</title>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="204"/>
                    <measurement group_id="O3" value="197"/>
                    <measurement group_id="O4" value="192"/>
                  </measurement_list>
                </category>
                <category>
                  <title>non-cataract cases</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5409"/>
                    <measurement group_id="O2" value="5469"/>
                    <measurement group_id="O3" value="5436"/>
                    <measurement group_id="O4" value="5442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.81</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Advanced AMD</title>
        <description>Advanced AMD was defined as the occurrence of disciform scars, or geographic atrophy or retinal pigment epithelium (RPE) detachment in either or both eyes at AMD diagnosis.</description>
        <time_frame>Every 6 months, up to 7 years</time_frame>
        <population>Marginal analyses were performed with arms pooled based on active vs. placebo selenium or vitamin E.</population>
        <group_list>
          <group group_id="O1">
            <title>AMD: Selenium Active</title>
            <description>Patients received selenium and either Vitamin E or vitamin E placebo daily for 7 - 12 years&#xD;
Selenium: 200 mcg daily for 7 - 12 years&#xD;
Vitamin E: 400 IU daily by mouth for 7 - 12 years&#xD;
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years</description>
          </group>
          <group group_id="O2">
            <title>AMD: Selenium Placebo</title>
            <description>Patients received selenium placebo and either Vitamin E or vitamin E placebo daily for 7 - 12 years&#xD;
Selenium placebo: 1 pill by mouth daily for 7 - 12 years&#xD;
Vitamin E: 400 IU daily by mouth for 7 - 12 years&#xD;
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years</description>
          </group>
          <group group_id="O3">
            <title>AMD: Vitamin E Active</title>
            <description>Patients received vitamin E and either selenium or selenium placebo daily for 7 - 12 years&#xD;
Vitamin E: 400 IU daily by mouth for 7 - 12 years&#xD;
Selenium: 200 mcg daily for 7 - 12 years&#xD;
Selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
          </group>
          <group group_id="O4">
            <title>AMD: Vitamin E Placebo</title>
            <description>Patients received vitamin E placebo and either selenium or selenium placebo daily for 7 - 12 years&#xD;
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years&#xD;
Selenium: 200 mcg daily for 7 - 12 years&#xD;
Selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Advanced AMD</title>
          <description>Advanced AMD was defined as the occurrence of disciform scars, or geographic atrophy or retinal pigment epithelium (RPE) detachment in either or both eyes at AMD diagnosis.</description>
          <population>Marginal analyses were performed with arms pooled based on active vs. placebo selenium or vitamin E.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6690"/>
                <count group_id="O2" value="6699"/>
                <count group_id="O3" value="6686"/>
                <count group_id="O4" value="6703"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Advanced AMD cases</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>non-advanced AMD cases</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6680"/>
                    <measurement group_id="O2" value="6695"/>
                    <measurement group_id="O3" value="6679"/>
                    <measurement group_id="O4" value="6696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for number of participants with advanced AMD in SEE sites during pill-taking for selenium</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>7.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for number of participants with advanced AMD in SEE sites during pill-taking for vitamin E</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>2.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Underwent Cataract Extraction</title>
        <description>Cataract extraction was defined as the surgical removal of an incident cataract.</description>
        <time_frame>Every 6 months, up to 7 years</time_frame>
        <population>Marginal analyses were performed with arms pooled based on active vs. placebo selenium or vitamin E.</population>
        <group_list>
          <group group_id="O1">
            <title>Cataract: Selenium Active</title>
            <description>Patients received selenium and either vitamin E or vitamin E placebo daily for 7 - 12 years&#xD;
Selenium: 200 mcg daily for 7 - 12 years&#xD;
Vitamin E: 400 IU daily by mouth for 7 - 12 years&#xD;
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years</description>
          </group>
          <group group_id="O2">
            <title>Cataract: Selenium Placebo</title>
            <description>Patients received selenium placebo and either vitamin E or vitamin E placebo daily for 7 - 12 years&#xD;
Selenium placebo: 1 pill by mouth daily for 7 - 12 years&#xD;
Vitamin E: 400 IU daily by mouth for 7 - 12 years&#xD;
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years</description>
          </group>
          <group group_id="O3">
            <title>Cataract: Vitamin E Active</title>
            <description>Patients received vitamin E and either selenium or selenium placebo daily for 7 - 12 years&#xD;
Vitamin E: 400 IU daily by mouth for 7 - 12 years&#xD;
Selenium: 200 mcg daily for 7 - 12 years&#xD;
Selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
          </group>
          <group group_id="O4">
            <title>Cataract: Vitamin E Placebo</title>
            <description>Patients received vitamin E placebo and either selenium or selenium placebo daily for 7 - 12 years&#xD;
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years&#xD;
Selenium: 200 mcg daily for 7 - 12 years&#xD;
Selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Underwent Cataract Extraction</title>
          <description>Cataract extraction was defined as the surgical removal of an incident cataract.</description>
          <population>Marginal analyses were performed with arms pooled based on active vs. placebo selenium or vitamin E.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5594"/>
                <count group_id="O2" value="5673"/>
                <count group_id="O3" value="5633"/>
                <count group_id="O4" value="5634"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Cataract extraction cases</title>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="114"/>
                    <measurement group_id="O4" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>non-cataract extraction cases</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5495"/>
                    <measurement group_id="O2" value="5553"/>
                    <measurement group_id="O3" value="5519"/>
                    <measurement group_id="O4" value="5529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Every 6 months while the participant is receiving study supplements, up to 7 years</time_frame>
      <desc>There are no Adverse Events (AE) associated with this trial. All AEs were reported for the parent trial (SELECT - S0000). Included below are the AEs for the participants on this trial that were included in the primary analysis. These AEs were also reported for the parent trial.</desc>
      <group_list>
        <group group_id="E1">
          <title>Selenium + Vitamin E Placebo</title>
          <description>Selenium + Vitamin E placebo</description>
        </group>
        <group group_id="E2">
          <title>Selenium + Vitamin E</title>
          <description>Selenium + Vitamin E</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="E4">
          <title>Vitamin E + Selenium Placebo</title>
          <description>Vitamin E + Selenium placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="159" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="150" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="147" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="3374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia, NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Cardiovascular-other</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Conduction abnormality/block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>LVEF decrease/CHF</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Vision,NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Melena/ GI bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional symptoms-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Hemorrhage w/o 3-4 thrombocyt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Reportable adverse event, NOS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="3374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver-clinical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory infect w/o neutrop</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Respiratory infection, unk ANC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Surgery-hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Second primary</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Emphysema/COPD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Peripheral arterial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3374"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3374"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="243" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="243" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="261" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="267" subjects_at_risk="3374"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="243" subjects_at_risk="3374"/>
                <counts group_id="E2" subjects_affected="243" subjects_at_risk="3356"/>
                <counts group_id="E3" subjects_affected="261" subjects_at_risk="3366"/>
                <counts group_id="E4" subjects_affected="267" subjects_at_risk="3374"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>SELECT/S0000B Statistician</name_or_title>
      <organization>SWOG Statistical Center</organization>
      <phone>2066674623</phone>
      <email>adarke@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

